GSK’s Seroxat pay-for-delay deals may restrict competition: AG

23-01-2020

Sarah Morgan

GSK’s Seroxat pay-for-delay deals may restrict competition: AG

Willy Barton / Shutterstock.com

GlaxoSmithKline (GSK) may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union (CJEU).


GSK, pay-for-delay, antidepressant, CJEU, Advocate general, generics, competition law

LSIPR